Section 4 of 6
Clinical evidence
146 evidence topics · 44 sources
Study summaries
REVEAL pivotal
Objective
Registered objectives of NCT05606614
Role of the pivotal trial in the development plan
Location and study date
Country of the pivotal trial
Registered sites for NCT05606614 (Parts A and B combined)
| Site | Registry record |
|---|---|
| Duarte, California, United States | “City of Hope” |
| La Jolla, California, United States | “UC San Diego” |
| Oakland, California, United States | “UC San Francisco Benioff Children's Hospital” |
| Chicago, Illinois, United States | “Rush University Medical Center” |
| Baltimore, Maryland, United States | “Kennedy Krieger Institute” |
| Boston, Massachusetts, United States | “Boston Children's Hospital” |
| St Louis, Missouri, United States | “Washington University, St. Louis” |
| Dallas, Texas, United States | “UT Southwestern Children's Medical Center” |
| Montreal, Quebec, Canada | “CHU St. Justine” |
Study design
Single-arm, open-label design with participants as their own control
Registry design: phase 1/2/3 record with outcome assessor masking
FDA written alignment on key design elements
Finalized protocol and statistical analysis plan with a 6-month interim analysis
Natural history external reference: Rett Syndrome Natural History Study
Natural history external reference: trial-aligned analysis cohort and simulated control cohorts
FDA draft guidance on single-arm trials using participants as their own control
Blinded central rating of pre- and post-treatment videos
Eligibility criteria
Registered inclusion and exclusion criteria
Developmental plateau population aged 6 years and older
Rationale for the minimum age of 6 years
Milestone-level eligibility at screening and baseline
Treatment
Registered intervention and arm
Single lumbar intrathecal administration of the high dose
Study outcomes
Rationale for using Rett syndrome developmental milestone assessment response as the primary endpoint
Registered primary outcome of Part B
Primary endpoint definition and key secondary endpoints
The 28 developmental milestones
Selection of the 28 milestones from the natural history study
Natural history: developmental plateau after 6 years of age in the Taysha-funded analysis
Natural history: skill gain, loss, and regain in 1228 females with classic Rett syndrome
“The occurrence and time of gain, loss, and regain of 51 developmental skills was collected during in-person visits in the RTT Natural History Study from 1228 females with Classic RTT and a pathogenic loss-of-function variant in MECP2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regain of lost skills was infrequent for most skills, occurred mainly before 6 years old, and within 2 years of loss. After 6 years old, the incidence of either gaining or regaining skills was low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of gain or regain of skills beyond 6 years old suggest that any functional gains in these skills after a clinical intervention would represent an important indicator of efficacy as a clinical trial endpoint in RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this restricted set of developmental skills, the percentage of participants who gained at least one of these 38 skills fell below 5% per year after 6 years of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: advantages of developmental endpoints in trials that cannot be double-blind
“This is especially critical for clinical trials that preclude conducting studies in a double-blind fashion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The advantages of these developmental endpoints are: (1) they are easily defined, (2) binary, and (3) likely to be emergent with an effective treatment paradigm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“trials to define the expected trajectory and likelihood of gain or regain in an untreated cohort as a comparator to participants in an open label trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: earlier analysis of developmental skills
“Early developmental skills were acquired by many, but clear differences from normal emerged, particularly in skills expected after age 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data may serve for planning and interpretation of early intervention studies in RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychometric validation of the RS-DMA in the RESUME study
RS-DMA milestone with lower rater agreement: identifies body parts
RS-DMA historical caregiver interview compared with performative assessment
Limitations of existing Rett syndrome outcome assessments for single-arm designs
FDA interactions on the responder definition and the assessment
Caregiver views on meaningful milestone gains
Key secondary endpoint instrument: Revised Motor Behavior Assessment
“Using data from a natural history study (n = 1,075), we examined the factor structure, internal consistency, and validity of the clinician-reported Motor Behavior Assessment scale (MBA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The analysis resulted in a five-factor model: (1) motor dysfunction, (2) functional skills, (3) social skills, (4) aberrant behavior, and (5) respiratory behaviors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further work is needed to evaluate this measure longitudinally and to add items related to the RTT phenotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint instrument: Clinical Global Impression scales with Rett-specific anchors
“Despite its favorable assay sensitivity in clinical trials, as a global measure, the Clinical Global Impression Scale is not specific to the signs and symptoms of the disorder under study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Development of key anchors for the scale, specific to the disorder being assessed, holds promise for enhancing the validity and reliability of the measure for disorders such as Rett syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Validation status of Rett syndrome outcome measures
“Reliability, validity, and responsiveness profiles were mostly incomplete; there were limited content validation data, particularly parent-informed relevance, comprehensiveness and comprehensibility of items; and no data on meaningful change or cross-cultural validity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Validity data are not available although evidence of responsiveness was suggested in the paediatric Phase 2 [39] and 3 [14] trofinetide trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size and power
Overenrollment to 17 participants
Description of analysis sets
Null hypothesis and success threshold
Derivation of the 6.7% null threshold
Plateau-anchored, baseline-adjusted aggregate responder analysis
Primary analysis, interim analysis, and rater allocation by time point
Results
Participant disposition
Acute post-dosing safety monitoring period completed
Baseline characteristics
Age distribution of dosed participants
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related serious adverse event: peripheral sensory neuropathy
Pooled safety across the REVEAL Phase 1/2, REVEAL pivotal, and ASPIRE trials: November 2026 cutoff
Study limitations
Summary
- Design and comparator: REVEAL Pivotal is a single-arm, open-label trial with no concurrent control. Efficacy is judged against an external null response rate of 6.7% (1 of 15 participants) derived from the Rett Syndrome Natural History Study, with a 33% response rate (5 of 15) as the minimum threshold for success. The natural history analysis cites sham lumbar puncture, functional unblinding from required immunosuppression, and delayed treatment as ethical and methodological obstacles to a controlled design.
- Derivation of the null: the 28 milestones, the minimum age of 6 years, the time-since-loss rules, and the 6.7% threshold come from analyses of Rett Syndrome Natural History Study data. The highest spontaneous gain rate observed after 6 years of age was 3%, corresponding to 0.45 expected spontaneous responders among 15 participants, and one spontaneous responder (6.7%) was selected as the null threshold because the responder count must be discrete.
- Baseline and milestone eligibility: a milestone is eligible for gain or regain when medical history confirms that it was never achieved or was lost sufficiently long ago and an in-clinic video assessment confirms that it is not demonstrated. In the RESUME validation study, agreement between the RS-DMA historical caregiver interview and the performative RS-DMA averaged 81.8%, with more than one-third of items at slight or fair agreement.
- Endpoint validation: the RS-DMA was validated in a non-interventional study of 13 participants. Inter-rater agreement was substantial to excellent for 27 of the 28 milestones and fair for identifying body parts, and 83% of video recordings were rated feasible for central rating. A responder is a participant who gains or regains at least 1 of 28 milestones, so a single milestone of any type meets the definition.
- Blinding and assessment: only central raters are masked, and only to the timing of each video. Milestone demonstration is a performed task administered in clinic. The 2025 FDA draft guidance states that self-controlled studies can be particularly persuasive when a condition is universally degenerative in all affected individuals and the intervention is expected to lead to improvement, and that objectively measured endpoints that are not effort-dependent are critical to interpreting self-controlled or other non-blinded trials. The natural history data describe a developmental plateau from 6 years of age and slow loss of gross motor skills during Stage III.
- Secondary endpoints: the key secondary measures are the R-MBA and CGI-I. One publication describes the reliability, validity, and responsiveness profiles of the outcome measures it assessed as mostly incomplete, with no data on meaningful change, and the psychometric study of the clinician-reported MBA called for longitudinal evaluation of the measure.
- Size, timing, and analysis: 17 females aged 6 to under 22 years were dosed against a planned 15. A BLA may rest on a 6-month interim analysis, while the registered primary outcome runs from baseline through week 52 and the statistical analysis plan names a 12-month primary analysis. The registered primary outcome is worded as a change from baseline in the percentage of responders, which differs from the response rate the sponsor describes. No published protocol or statistical analysis plan was identified.
- Population and extrapolation: eligibility is limited to females with classic Rett syndrome and a loss-of-function MECP2 variant, excluding atypical Rett syndrome and participants needing invasive ventilation. The sponsor plans to extrapolate efficacy to children aged 2 to under 6 years, an age range in which the natural history analysis reports spontaneous first-time gain of a single milestone as high as 97%.
- Results and safety reporting: no efficacy results have been reported; topline interim data are expected in the first half of 2027. Safety has been reported in company filings and press releases, mostly pooled with the phase 1/2 and ASPIRE trials (33 participants). One pivotal participant had a treatment-related Grade 2 serious adverse event of peripheral sensory neuropathy about 6 weeks after dosing in July 2026; no adverse event table specific to the pivotal trial was identified.
- Reporting consistency: the third quarter 2026 Form 10-Q states that the pivotal trial is taking place in the United States, while the combined registry record lists a site in Montreal and the sponsor reported a No Objection Letter from Health Canada before site activation.
ASPIRE
Objective
Registry objective and official title
Regulatory purpose: safety data to support a label for patients aged 2 years and older
Location and study date
Registry record: dates, status, and sites
| Field | Quoted record |
|---|---|
| Protocol number | “TSHA-102-CL-201” |
| Study start | “2026-05-08” |
| Primary completion (estimated) | “2031-06” |
| Overall status | “Active, not recruiting” |
| Site | “University of Alabama at Birmingham” |
| Site | “Rush University Medical Center” |
| Site | “Boston Children's Hospital” |
Enrollment across multiple sites and dosing timeline
Study design
Single-group, open-label phase 3 design with blinded central raters
Extrapolation design: efficacy from REVEAL pivotal, safety from ASPIRE
Eligibility criteria
Inclusion criteria
Treatment
Single intrathecal dose adjusted for brain volume
High dose scaled to the lower brain volume of children aged 2 to less than 4 years
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Primary endpoint: treatment-emergent adverse events through week 25
Safety data requirement agreed with the FDA
Spontaneous milestone gain before 6 years of age limits efficacy assessment
Regulatory framework: pediatric extrapolation and additional safety data
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of three participants, overenrolled to four
Description of analysis sets
No evidence found.
Results
Participant disposition
All participants past the acute post-dosing monitoring period
Baseline characteristics
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Pooled safety across REVEAL Phase 1/2, REVEAL pivotal, and ASPIRE as of November 2026
Study limitations
Summary
- ASPIRE is a multicenter, open-label study in which every participant receives TSHA-102. It dosed 4 participants (3 planned) aged 2 to less than 4 years, and the registry lists 3 sites.
- The registry primary endpoint is the proportion of participants experiencing any treatment-emergent adverse events and serious adverse events from baseline through week 25. The planned BLA is to include a minimum of 3 months of ASPIRE safety data, which is shorter than the 25-week primary safety analysis period and the 5-year follow-up period.
- No ASPIRE-specific safety results have been reported. The available safety statement pools 33 participants across REVEAL Phase 1/2 (12), REVEAL pivotal (17), and ASPIRE (4) and reports the absence of severe treatment-related serious adverse events and dose-limiting toxicities as of the November 2026 data cutoff; it does not report the type or frequency of other adverse events in the 4 ASPIRE participants.
- No efficacy results have been reported. Efficacy in children aged 2 to less than 6 years is to be extrapolated from REVEAL pivotal participants aged 6 to less than 22 years in the developmental plateau population. The natural history analysis reports spontaneous first-time gain of a single milestone as high as 97% before 6 years of age, and states that including younger participants without explicit age accounting could increase background spontaneous gain.
- None of the three trials has dosed children aged 4 to less than 6 years: ASPIRE enrolls children aged 2 to less than 4 years, the 12 REVEAL Part A participants were 6 to 21 years of age at dosing, and REVEAL pivotal enrolls participants aged 6 to less than 22 years.
- The dose is 1.0 × 10¹⁵ total vector genomes adjusted for brain volume; no description of the scaling method or of the doses administered was identified.
- The registry states that other protocol-defined inclusion and exclusion criteria may apply, and no published protocol, statistical analysis plan, or description of analysis sets was identified.
- All information comes from the sponsor's registry record, press releases, and SEC filings and from a natural history analysis. The company's August 2026 corporate presentation describes efficacy data for females aged 2 to less than 4 years as to be extrapolated from the pivotal trial, while the Form 10-K and the third quarter 2026 Form 10-Q describe extrapolation to the 2 to less than 6-year-old population.
REVEAL part A
Objective
Objectives of the pooled REVEAL Part A analysis
Adolescent and adult trial (NCT05606614 Part A): registered objective
Pediatric trial (NCT06152237): registered objective
Location and study date
Adolescent and adult trial (NCT05606614): registry dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2023-03-06” |
| Primary completion (estimated) | “2031-06” |
| Study completion (estimated) | “2031-06” |
| Last update posted | “2026-07-07” |
Adolescent and adult trial (NCT05606614): registered sites for Parts A and B
| Country | Registry record |
|---|---|
| United States | “City of Hope” |
| United States | “UC San Diego” |
| United States | “UC San Francisco Benioff Children's Hospital” |
| United States | “Rush University Medical Center” |
| United States | “Kennedy Krieger Institute” |
| United States | “Boston Children's Hospital” |
| United States | “Washington University, St. Louis” |
| United States | “UT Southwestern Children's Medical Center” |
| Canada | “CHU St. Justine” |
Pediatric trial (NCT06152237): registry dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2023-12-12” |
| Primary completion (estimated) | “2028-11-02” |
| Study completion (estimated) | “2031-11-02” |
| Last update posted | “2025-10-15” |
Pediatric trial (NCT06152237): registered sites
| Country | Registry record |
|---|---|
| United States | “Rush University Medical Center & Children's Hospital” |
| United States | “Gillette Children's Specialty Healthcare” |
| United States | “Washington University, St. Louis” |
| Canada | “CHU Ste-Justine” |
| United Kingdom | “Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust” |
First adult participant dosed in Canada, June 2023
First pediatric participant dosed in the United States, January 2024, and United Kingdom authorization
Expansion of the adolescent and adult trial into the United States, February 2024
Completion of Part A dosing and data cutoffs
Study design
Pooled design as reported with the 12-month results
Two first-in-human trials described together as Part A
Adolescent and adult trial (NCT05606614): registered design elements
| Design element | Registry record |
|---|---|
| Phase (record now covers Parts A and B) | “Phase 3” |
| Allocation | “Non-Randomized” |
| Intervention model | “Sequential Assignment” |
| Masking | “Single (Outcomes Assessor)” |
| Masking description | “Central raters assessing the gain or regain of a developmental milestone from videos are blinded to the timing of each video.” |
| Follow-up | “Each participant will be followed for the observation period of 5 years after TSHA-102 administration in Part A and B.” |
Pediatric trial (NCT06152237): registered design elements
| Design element | Registry record |
|---|---|
| Allocation | “Randomized” |
| Intervention model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
| Study duration | “The study duration is up to 6 years.” |
Dose-escalation rules with Independent Data Monitoring Committee review (pediatric protocol design)
Independent Data Monitoring Committee approval of dose escalation
Part B design as planned before the pivotal trial replaced it
Eligibility criteria
Adolescent and adult trial (NCT05606614): registered criteria
Adolescent and adult trial: eligibility extended from adults to age 12 and older, November 2023
Pediatric trial (NCT06152237): registered criteria
Treatment
Registered dose levels (adolescent and adult trial)
Dose cohorts pooled across both trials
Immunosuppression and intrathecal administration
Immunosuppression taper timing in the first two adult participants
Low dose as stated before the first participant was dosed
Comparability of Part A clinical material with the commercial process
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary outcome: adolescent and adult trial
Registered primary and exploratory outcomes: pediatric trial
Safety as the first objective of a first-in-human dose escalation
Developmental milestone gain or regain as the primary evidence of efficacy
Supplemental efficacy scales: MSEL-A, ORCA, and R-MBA
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment per trial
Enrollment recorded in the registries
| Field | Registry record |
|---|---|
| Enrollment (actual) | “6” |
Accrual over time
Participants analyzed at the May 2026 data cutoff
Description of analysis sets
Analysis set and data cutoff for the 12-month results
Natural history comparator sample sizes for R-MBA
| Time point | TSHA-102 | Natural history |
|---|---|---|
| 6 months | “TSHA-102 (N=12) SD=10.18” | “Natural History (N=75) SD= 5.97” |
| 12 months | “TSHA-102 (N=12) SD=8.86” | “Natural History (N=196) SD= 5.73” |
Planned analysis relative to each participant's baseline (pediatric protocol design)
Earlier analyses drawn from the electronic data capture system
Results
Participant disposition
All 12 participants followed for at least 12 months
Participants with data beyond 12 months
Baseline characteristics
Age, severity, and genotype of the 12 participants
Individual participants: age at dosing, baseline CGI-S, and follow-up
| Cohort and participant | Age at dosing (years) | Baseline CGI-S score | Post-treatment follow-up (months) |
|---|---|---|---|
| Low dose, participant 1 | “20” | “6” | “30” |
| Low dose, participant 2 | “21” | “4” | “30” |
| Low dose, participant 3 | “6” | “5” | “24” |
| Low dose, participant 4 | “7” | “4” | “24” |
| High dose, participant 1 | “15” | “5” | “18” |
| High dose, participant 2 | “21” | “5” | “18” |
| High dose, participant 3 | “8” | “5” | “18” |
| High dose, participant 4 | “15” | “5” | “12” |
| High dose, participant 5 | “16” | “5” | “12” |
| High dose, participant 6 | “6” | “4” | “12” |
| High dose, participant 7 | “7” | “6” | “12” |
| High dose, participant 8 | “6” | “5” | “12” |
First two adult participants: stage four disease
“20-year-old female at the time of dosing” (opens the source at this quote in a new tab)
“21-year-old female at the time of dosing” (opens the source at this quote in a new tab)
“Large MECP2 deletion affecting exons 3 and 4” (opens the source at this quote in a new tab)
“Missense MECP2 mutation (R133C)” (opens the source at this quote in a new tab)
First two pediatric participants: stage three disease
“6-year-old female at the time of dosing” (opens the source at this quote in a new tab)
“7-year-old female at the time of dosing” (opens the source at this quote in a new tab)
“Nonsense MECP2 mutation (R255X)” (opens the source at this quote in a new tab)
“Missense MECP2 mutation (R306C)” (opens the source at this quote in a new tab)
Efficacy results
Responses at 6, 12, and at least 18 months (May 2026 data cutoff)
| Endpoint | 6 months (N=12) | 12 months (N=12) | 18 months or more (N=7) |
|---|---|---|---|
| Participants who gained or regained at least one developmental milestone | “83%” | “100%” | “100%” |
| Average functional gains per participant | “22” | “23” | “26” |
| R-MBA mean score change versus natural history | “-11.0 P = 0.0011” | “-10.3 P = 0.0002” | “-11.0 P = 0.0046” |
| Participants with CGI-I score of 3 or less at multiple post-treatment assessments | “100%” | “100%” | “100%” |
| Participants with CGI-S total score improvement | “25%” | “25%” | “57%” |
Number of developmental milestones and additional skills
R-MBA mean change from baseline versus natural history, by dose
| Time point | TSHA-102 mean change | Natural history mean change | P value |
|---|---|---|---|
| 6 months | “-11.0” | “-0.81” | “P = 0.0011” |
| 12 months | “-10.3” | “-0.62” | “P = 0.0002” |
Dose comparison at the May 2025 data cutoff (10 participants)
| Endpoint | Low-dose cohort | High-dose cohort |
|---|---|---|
| Developmental milestone responder rate at 6 months | “75%” | “83%” |
| R-MBA mean score improvement at 6 months | “-9.8” | “-12.2” |
| R-MBA mean score improvement at 9 months or more | “-11.5” | “-18.0” |
| Mean CGI-I score at 6 months | “2.3” | “2.0” |
| Mean CGI-I score at 9 months or more | “2.8” | “1.0” |
| Participants with CGI-S improvement at latest visit | “25%” | “33%” |
Supplemental analysis at the May 2025 data cutoff
Health-related quality of life and patient-reported outcomes
Caregiver-reported communication (ORCA)
Caregiver global impression (PGI-I) in the first adult participants
Caregiver-reported behavior questionnaire (RSBQ)
Health-related quality of life instrument results
No evidence found.
Safety results
Treatment-emergent adverse events across the 12 participants (May 2026 data cutoff)
Most common treatment-related events, severity, and seizures
Transaminase pattern and other events at the May 2025 data cutoff
Events in the first four low-dose participants, including immunosuppression-related events
Safety across Part A, the pivotal trial, and ASPIRE (November 2026 data cutoff)
Study limitations
Summary
- Pooled sample: REVEAL Part A combines two separately registered phase 1/2 dose-escalation trials, NCT05606614 Part A (females aged 12 to <22 years) and NCT06152237 (females aged 5 to 8 years), into one analysis of 12 participants, 4 at the low dose and 8 at the high dose. Comparisons between doses rest on groups of 4 and 8 participants, and comparisons between age groups on 6 pediatric and 6 adolescent or adult participants.
- No concurrent control: Part A of both trials is open label, and the 2026 poster describes each participant as their own control. Efficacy is judged against each participant's baseline and against external data from the Rett syndrome Natural History Study. The R-MBA comparison draws on natural history samples of 75 participants at 6 months and 196 at 12 months, with MBA scores converted to R-MBA.
- Efficacy endpoints outside the registered Part A outcomes: the registered primary outcome of Part A in both trials is the proportion or incidence of participants with treatment-emergent adverse events and serious adverse events. Developmental milestone gain or regain, the primary evidence of efficacy in the 2026 poster, is registered as the primary outcome of Part B, and the poster describes evaluation criteria applied to available video-evidenced milestone data. The counts of additional skills derived from the MSEL-A, ORCA, and R-MBA come from a supplemental analysis, with ORCA data for 8 and MSEL-A data for 7 of the 12 participants; an earlier company announcement reported 165 additional skills or improvements across 10 participants from the same scales.
- Masking: the pediatric trial is registered with no masking. In the adolescent and adult trial, only the central raters of milestone videos are masked, and only to the timing of each video. The R-MBA is a clinician-reported evaluation and ORCA a caregiver-reported evaluation, collected in open-label trials.
- Follow-up: all 12 participants had at least 12 months of follow-up (range 12 to 30 months), and results at 18 months or more rest on 7 participants.
- Concomitant immunosuppression: prednisolone and sirolimus begin 7 days before dosing and are tapered over the following months. In the company's 2024 first-cohort data presentation, the most common event, vomiting, was described as a known risk of sirolimus, and eight nonserious events were attributed to immunosuppression.
- Heterogeneous population: participants were 6 to 21 years of age at dosing, had baseline CGI-S scores of 4 to 6, and carried varied MECP2 mutations; the pediatric trial was opened to stage three Rett syndrome and the adolescent and adult trial to stage four Rett syndrome.
- Sponsor reporting: all results come from Taysha press releases, SEC filings, presentations, and congress posters, and the 2025 poster states that its data came from the electronic data capture system and were subject to change.
- Inconsistencies between documents: the low dose was stated as 5x10^14 vg in June 2023 and as 5.7x10^14 vg in the registry and the third quarter 2026 Form 10-Q. The third quarter 2026 Form 10-Q describes both trials as randomized and NCT06152237 lists randomized allocation, while NCT05606614 lists non-randomized allocation, the 2023 pediatric design poster describes Part A as a single-arm dose escalation, and the 2024 first-cohort presentation plans randomization in Part B. The 2024 announcements planned at least 3 participants per dose in the pediatric trial and 3 high-dose participants in the adolescent and adult trial; NCT05606614 enrolled 2 low-dose and 4 high-dose participants, and the 12 Part A participants comprised 4 low-dose and 8 high-dose participants.